NCT00539591 2025-12-23
Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma
St. Jude Children's Research Hospital
Phase 2 Active not recruiting
Clinical Trials
17 trialsNCT00049530 2023-06-29
PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT02218164 2022-10-07
Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT02089685 2022-09-13
MK-3475-029
Merck Sharp & Dohme LLC
Phase 1/2 Completed
NCT02112032 2021-05-05
Treatment of Advanced Melanoma With MK-3475 and Peginterferon
University of Pittsburgh
Phase 1 Completed
NCT00525031 2020-09-23
Temozolomide Alone or With Pegylated Interferon-Alpha 2b (PGI) in Melanoma Patients
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02379195 2020-01-22
Peginterferon and TIL Therapy for Metastatic Melanoma
Herlev Hospital
Phase 1/2 Completed
NCT03552549 2019-07-24
SCH 54031 PEG12000 Interferon Alfa-2b (PEG Intron, MK-4031) vs. INTRON®A (SCH 30500, MK-2958) as Adjuvant Therapy for Melanoma (C98-135, MK-4031-002)
Merck Sharp & Dohme LLC
Phase 2/3 Terminated
NCT00724061 2018-12-12
Study of Pegylated Interferon-Alfa 2b in Combination With PUVA Therapy In CTCL
Northwestern University
Phase NA Terminated
NCT00791271 2018-11-09
Parallel Phase I/II Trial of Decitabine and Peg-Interferon in Melanoma: Phase I Portion
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT02155322 2018-08-23
A Phase II Study of Pegylated Interferon Alfa-2b for the Adjuvant Treatment of Melanoma Subjects in Russia (MK-4031-400)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT00457418 2017-06-07
High-Dose PEG-Intron Pharmacokinetic Study in Patients With Melanoma (Study P04831 AM2)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT01496807 2017-04-28
Yervoy With Sylatron Unresectable Stage 3 or 4 Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT00861406 2017-03-03
Adjuvant Therapy of Pegylated Interferon- 2b Plus Melanoma Peptide Vaccine
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00746746 2011-01-13
A Phase II Study of an Anti-Tumor Immunotherapy Regimen Comprised of Pegylated Interferon-Alpha 2b and HyperAcute Melanoma Vaccine for Subjects With Advanced Melanoma
Ochsner Health System
Phase 2 Unknown
NCT00623402 2011-01-12
SoraPeg
University Hospital Schleswig-Holstein
Phase 2 Completed
NCT00221702 2010-10-13
EADO
University Hospital, Bordeaux
Phase 3 Completed